If any two of the following factors are present, the mother is considered at risk:
- First pregnancy at the age of 40 or above.
- The mother has a body mass index (BMI) score of 35kg/m2 or above during initial screening.
- The mother has a family history of pre-eclampsia.
Screening for the aforementioned risk factors allows medical staff to identify PE risk in only 30% of cases.
However, now there are screening techniques available which can identify the mother’s risk level, and provide protection against the occurrence of PE. Able to be carried out from the 11th to 13th week plus 6 days of a pregnancy, this screening technique enables identification in up to 90% of cases. The screening process involves a uterine artery Doppler ultrasound examination of both the right and left sides to be carried out in conjunction with a blood test in order to assess the levels of placental growth factor (PIGF), which are proteins that promotes vessel formation. This method is applied because women who are suffering from abnormal placental development will have lower-than-normal PIGF levels.
The screening requires inputting the uterine artery circulation scores of both sides, the PIGF level, and the maternal blood pressure ratings into software, which then calculates the mother’s personal preeclampsia risk. If the risk is found to be high, protection can be offered in the form of medication to be taken from the 16th week until the 36th week of the pregnancy, which will reduce the risk of PE occurring before the 37th week by up to 70%.